- Home
- JELD vs FHTX Comparison
JELD vs FHTX Comparison
Compare JELD & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JELD | FHTX |
|---|---|---|
| Founded | 1960 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Forest Products | Medicinal Chemicals and Botanical Products |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 152.7M | 111.1M |
| IPO Year | 2016 | 2020 |
Fundamental Metrics
Financial Performance| Metric | JELD | FHTX |
|---|---|---|
| Price | $1.39 | $2.03 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 10 |
| Target Price | $1.93 | ★ $4.17 |
| AVG Volume (30 Days) | ★ 1.5M | 1.2M |
| Earning Date | 11-03-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.32 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,211,181,000.00 | $30,909,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.28 | $15.98 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 36.75 |
| 52 Week Low | $0.93 | $1.79 |
| 52 Week High | $4.90 | $7.61 |
Technical Indicators
Market Signals| Indicator | JELD | FHTX |
|---|---|---|
| Relative Strength Index (RSI) | 41.39 | 25.12 |
| Support Level | $1.36 | $1.79 |
| Resistance Level | $2.25 | $5.27 |
| Average True Range (ATR) | 0.14 | 0.14 |
| MACD | -0.01 | 0.11 |
| Stochastic Oscillator | 28.03 | 61.43 |
Price Performance
Historical ComparisonAbout JELD JELD-WEN Holding Inc.
JELD-WEN Holding Inc is engaged in door and window manufacturing. The company designs, produces, and distributes interior and exterior building products, offering a selection of doors, windows, walls, and related products. The products are used in the new construction of residential and non-residential buildings. The firm's operating segments are North America, and Europe. It generates a majority of its revenue from North America.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.